From a medical cardiologist and ACS expert perspective, can you identify which patients should undergo consideration for PCSK9-mediated LDL-C reduction and what risk factors should encourage CV specialists to pursue PCSK9-based therapies?

From a medical cardiologist and ACS expert perspective, can you identify which patients should undergo consideration for PCSK9-mediated LDL-C reduction and what risk factors should encourage CV specialists to pursue PCSK9-based therapies?

From a medical cardiologist and ACS expert perspective, can you identify which patients should undergo consideration for PCSK9-mediated LDL-C reduction and what risk factors should encourage CV specialists to pursue PCSK9-based therapies?


Created by

 CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Interventional Cardiologist's Perspective

Presenter

Shaun Goodman, MD, MSc, FRCPC, FACC, FESC, FAHA

Shaun Goodman, MD, MSc, FRCPC, FACC, FESC, FAHA

Associate Head, Division of Cardiology

Associate Head, Division of Cardiology St. Michael’s Hospital